Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain.
Adolescent
Adult
Aged
Aged, 80 and over
COVID-19
/ mortality
Child
Cohort Studies
Comorbidity
Databases, Factual
Female
Hospitalization
/ statistics & numerical data
Humans
Immunosuppression Therapy
/ adverse effects
Influenza, Human
/ epidemiology
Male
Middle Aged
Neoplasms
/ epidemiology
Outcome Assessment, Health Care
/ statistics & numerical data
Pandemics
Prevalence
Risk Factors
SARS-CoV-2
Spain
/ epidemiology
United States
/ epidemiology
Young Adult
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
25
02
2021
revised:
26
04
2021
accepted:
07
07
2021
pubmed:
18
7
2021
medline:
15
10
2021
entrez:
17
7
2021
Statut:
ppublish
Résumé
We described the demographics, cancer subtypes, comorbidities, and outcomes of patients with a history of cancer and coronavirus disease 2019 (COVID-19). Second, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza. We conducted a cohort study using eight routinely collected health care databases from Spain and the United States, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: (i) diagnosed with COVID-19, (ii) hospitalized with COVID-19, and (iii) hospitalized with influenza in 2017 to 2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes. We included 366,050 and 119,597 patients diagnosed and hospitalized with COVID-19, respectively. Prostate and breast cancers were the most frequent cancers (range: 5%-18% and 1%-14% in the diagnosed cohort, respectively). Hematologic malignancies were also frequent, with non-Hodgkin's lymphoma being among the five most common cancer subtypes in the diagnosed cohort. Overall, patients were aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 2% to 14% and from 6% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza ( Patients with a history of cancer and COVID-19 had multiple comorbidities and a high occurrence of COVID-19-related events. Hematologic malignancies were frequent. This study provides epidemiologic characteristics that can inform clinical care and etiologic studies.
Sections du résumé
BACKGROUND
We described the demographics, cancer subtypes, comorbidities, and outcomes of patients with a history of cancer and coronavirus disease 2019 (COVID-19). Second, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza.
METHODS
We conducted a cohort study using eight routinely collected health care databases from Spain and the United States, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: (i) diagnosed with COVID-19, (ii) hospitalized with COVID-19, and (iii) hospitalized with influenza in 2017 to 2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes.
RESULTS
We included 366,050 and 119,597 patients diagnosed and hospitalized with COVID-19, respectively. Prostate and breast cancers were the most frequent cancers (range: 5%-18% and 1%-14% in the diagnosed cohort, respectively). Hematologic malignancies were also frequent, with non-Hodgkin's lymphoma being among the five most common cancer subtypes in the diagnosed cohort. Overall, patients were aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 2% to 14% and from 6% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (
CONCLUSIONS
Patients with a history of cancer and COVID-19 had multiple comorbidities and a high occurrence of COVID-19-related events. Hematologic malignancies were frequent.
IMPACT
This study provides epidemiologic characteristics that can inform clinical care and etiologic studies.
Identifiants
pubmed: 34272262
pii: 1055-9965.EPI-21-0266
doi: 10.1158/1055-9965.EPI-21-0266
pmc: PMC8974356
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1884-1894Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
Int J Epidemiol. 2020 Oct 1;49(5):1468-1481
pubmed: 32887982
J Clin Oncol. 2020 Nov 20;38(33):3914-3924
pubmed: 32986528
Travel Med Infect Dis. 2020 Sep - Oct;37:101825
pubmed: 32763496
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
J Natl Cancer Inst. 2021 Jun 1;113(6):691-698
pubmed: 33031532
Inform Prim Care. 2011;19(3):135-45
pubmed: 22688222
Infect Dis Ther. 2017 Mar;6(1):69-83
pubmed: 28160269
ESMO Open. 2020 Sep;5(5):e000947
pubmed: 32978251
Eur J Cancer. 2020 Nov;139:43-50
pubmed: 32971510
J Am Med Inform Assoc. 2015 May;22(3):553-64
pubmed: 25670757
Nat Commun. 2020 Oct 6;11(1):5009
pubmed: 33024121
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Epidemiology. 2021 Jan;32(1):e2
pubmed: 33065609
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Nat Commun. 2020 Nov 12;11(1):5749
pubmed: 33184277
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Stud Health Technol Inform. 2015;216:574-8
pubmed: 26262116
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
Epidemiology. 2021 Jan;32(1):e1-e2
pubmed: 33065610
BMJ. 2020 May 22;369:m1985
pubmed: 32444460